Answers - Finance

Bonds may not be as visible in the media as stocks. There’s a lot more excitement that surrounds the area of stocks which makes them written about in the press a lot more. In fac

According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product

t, there are investors who have never heard of a bond even though they may have dabbled in the stock market and even looked at instruments like traded funds and futures. However,

; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

Examples of combination products may in

the fact remains that though bonds might not be as high profile and very often bring in lower returns, they are probably safer and healthier.

Stocks have a certain thrill that c

lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

mes attached with them. Picture yourself buying a stock and waking up the next day to watching it having risen in value by 10%. It’s heady, that feeling. And of course, investors

here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe

who watch their stocks doubling in a few months feel that they are very smart or they are very lucky! But inbuilt with the thrill factor is also the factor of risk. Stock prices

d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

Combination pro

are extremely volatile and what goes up, up, up can come crashing down in a moment, totally unexpectedly. Very often, the swings can be very large and rapid indeed.

Bonds on the

ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc

other hand have a more boring tag attached to them. But if you look closely, they do come in a variety to choose from – reliable and unexciting U.S. or corporate AAA 10-year ones

easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi

that give you a steady but small yield to junk bonds that can give you more than 15%! With bonds, too, you have to weigh them with the same principles as you would stocks – the

nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically

alculated risk factor against the rewards you hope to get. This is the standard trade-off. However, the risks in the bond market are considerably lower and what’s even more comfo

and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ

ting, they are easy to calculate.

You need more capital for the initial investment in bonds. You might only get one bond for a hundred shares of $10 stock. You’ll also find mutu

ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi

l funds that invest mainly in bonds and your broker could advise you about other options like ‘pay as you go’ plans. The trouble with bonds is the fact that you can’t trade them

ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

Following aspects would a

as easily as you would stocks. As far as stocks go, for most of us, it’s a matter of a few clicks of the mouse. Bonds however, require you to make that telephone call and not all

dd to the challenges in developing combination products:

Which markets to tap where the combination products can do fairly well?
Which combination prod

bonds can be traded through brokers. Bonds also attract a higher commission. It’s best to check with your broker who will list out the options for you.

When you are looking at t

cts are meaningful and rational?
Which therapeutic categories to select?
Which Combinations can address unmet needs of the patients?
Do combin

e short term, bonds are definitely less volatile. However, one thing they are sensitive to are interest rates. Bonds always have a coupon rate while shares have dividends which o

tions increase the patient compliance?
What would be the developing cost?
How to tackle the risks encountered during combination product developmen

ne could look at as interest being paid on the stocks though this could be sometimes skewed according to the whims of the management. Where bonds are concerned, the coupon rate i

t?

As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel

fixed at the time when they are issued. So if you are planning to sell your bonds, particularly before their date of maturity, this rate will be compared to other investments th

ping new procedures for reviewing their safety, efficacy and quality.

Professional from academic institutions, pharmaceutical industries, health care indust

t give interest. So you will find that the prices of bonds are affected by not only what their coupon rate is but also how far they have to go before their maturity. Bonds tend t

y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products

o be more influenced by government policies than stocks are. What could affect bonds are massive borrowings, which could mean the government issuing bonds or by setting the prime

.

As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de

rate lending rates or thanks to legislation that has an effect on insurance companies, banks or large institutions.

Therefore what seems to emerge is that it pays to have a dive

elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

Companies that provide selfless information through particip

sified portfolio. Whether you directly buy them or you possess them thanks to your mutual funds, bonds spell a lot more safety and would be a welcome addition to your investments

tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

HTTP = HTML link (for blogs, profiles,phorums):
<a href="http://www.answers.org.ua/article/102150/answers-Why-Bonds-May-Be-Better-Than-Stocks.html">Why Bonds May Be Better Than Stocks</a>

BB link (for phorums):
[url=http://www.answers.org.ua/article/102150/answers-Why-Bonds-May-Be-Better-Than-Stocks.html]Why Bonds May Be Better Than Stocks[/url]

You probably know by now that To be a successful affiliate marketer takes a ton of work. And to set up niche markets is also a challenge. Keyword research is the key to success.

If you do make a special offer on the confirmation email, it must be fact, and you cannot be offering this product at the same price elsewhere. It is best, therefore, to offer a product that you have...

If you are researching Forex information you may come across references to Tom DeMark trendlines. These trendlines are very specific and offer a higher degree of accuracy than general trendlines. Learn how to draw them and use them with caution.

Tags

Links

Answers - Why Bonds May Be Better Than Stocks

Related Articles: